全文获取类型
收费全文 | 2435篇 |
免费 | 49篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 32篇 |
妇产科学 | 8篇 |
基础医学 | 74篇 |
口腔科学 | 15篇 |
临床医学 | 984篇 |
内科学 | 64篇 |
皮肤病学 | 2篇 |
神经病学 | 502篇 |
特种医学 | 22篇 |
外科学 | 20篇 |
综合类 | 199篇 |
预防医学 | 65篇 |
眼科学 | 15篇 |
药学 | 180篇 |
中国医学 | 273篇 |
出版年
2023年 | 17篇 |
2022年 | 49篇 |
2021年 | 146篇 |
2020年 | 59篇 |
2019年 | 51篇 |
2018年 | 53篇 |
2017年 | 42篇 |
2016年 | 53篇 |
2015年 | 44篇 |
2014年 | 177篇 |
2013年 | 146篇 |
2012年 | 157篇 |
2011年 | 147篇 |
2010年 | 105篇 |
2009年 | 153篇 |
2008年 | 128篇 |
2007年 | 111篇 |
2006年 | 98篇 |
2005年 | 128篇 |
2004年 | 75篇 |
2003年 | 81篇 |
2002年 | 79篇 |
2001年 | 73篇 |
2000年 | 62篇 |
1999年 | 25篇 |
1998年 | 18篇 |
1997年 | 33篇 |
1996年 | 19篇 |
1995年 | 28篇 |
1994年 | 33篇 |
1993年 | 16篇 |
1992年 | 13篇 |
1991年 | 22篇 |
1990年 | 3篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 8篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有2500条查询结果,搜索用时 31 毫秒
11.
目的 探讨星状神经节阻滞 (stellate ganglion block,SGB)加服药物对偏头痛的治疗作用。方法 2 4 0例偏头痛患者按就诊顺序分为观察组与对照组 ,观察组接受 SGB治疗的同时 ,口服尼莫地平等药物。结果 观察组有效率达89.2 % ,高于对照组 (P<0 .0 5 ) ,其中治疗后完全无痛的病例 5 1.7% ,高于对照组 (P<0 .0 1) ,观察发现病程对于 SGB治疗偏头痛疗效影响较大 (P<0 .0 5 )。结论 SGB加服药物治疗偏头痛具有操作简单 ,起效快 ,疗效确切 ,副作用少等优点 ,值得临床推广应用。 相似文献
12.
The superior sagittal sinus (SSS) and the trigeminal ganglion (Vg) of anesthetized cats were stimulated electrically and field potentials in the upper cervical spinal cord and regional cerebral blood flow were recorded. Stimulation of the entire ganglion produced smaller field potential changes in two regions (medioventral area (MVA); dorsolateral area (DLA] of the upper spinal cord than did stimulation of the sagittal sinus (Vg/SSS response ratio = 17% for the MVA and 48% for the DLA). Stimulation of the trigeminal ganglion increased blood flow in only the frontal and parietal cortices (+93% and +33%), whereas stimulation of the sinus produced both larger changes in these areas (+137% and +139%) and also produced changes in regional cerebral blood flow in the thalamus (+122%). 相似文献
13.
目的采用电刺激大鼠上矢状窦(SSS)区硬脑膜,观察颈上交感神经节(SCG)摘除术前后在延髓和上颈段三叉神经脊束核一氧化氮合酶(NOS)阳性神经元数目的变化,以探讨交感神经系统在血管源性头痛(如偏头痛)涉及的伤害觉信息传递中的作用。方法以雄性SD大鼠(体重为220~250g)为实验对象,行颈上交感神经节摘除术后再手术暴露其SSS,然后电刺激SSS区硬脑膜,应用免疫组织化学染色技术,观察延髓和上颈段三叉神经脊束核NOS表达的变化。结果NOS免疫反应阳性神经元主要分布在三叉神经脊束核和上颈段脊髓的第Ⅰ、Ⅱ板层,双侧对称。假手术对照组、SCG摘除组每张切片的NOS阳性神经元数分别为150.2±10.3、223.0±11.6,SCG摘除组NOS阳性神经元数目较假手术对照组明显增加(P<0.05)。结论颈交感神经系统参与了头部血管源性疼痛(如偏头痛)中伤害性感觉信息导致的疼痛的产生、传导及调节过程。 相似文献
14.
The platelet and the neuron: Two cells in focus in migraine 总被引:1,自引:0,他引:1
Reports of platelet abnormalities in migraine are abundant, and the present paper discusses the role of platelets in the migraine aetiology. Platelets are considered good models for pre- and post-synaptic functions in serotonergic neurons. We propose that migraine is associated with a lowered threshold for stimulus response in both platelets and serotonergic neurons and that the alterations in platelet function reflect central serotonergic disturbances. The platelet abnormalities in migraine approach those found in depression, and there are several links between the two disorders. The clinical significance of platelet hyperactivity in migraineurs for the occurrence of thrombotic disorders is also discussed. Studies of platelet functions in migraine, using platelets as models for serotonergic neurons, may broaden our understanding of the neuronal processes that take place during a migraine attack. The platelet can also be an investigative tool for better understanding of the modes of action of anti-migraine drugs. 相似文献
15.
磁珠耳穴贴压治疗偏头痛临床观察 总被引:9,自引:2,他引:7
目的比较磁珠耳穴贴压治疗与服用西药治疗偏头痛的疗效差异。方法将偏头痛患者200例随机分为磁珠耳穴贴压组(观察组)和西药组(对照组),比较其对头部疼痛改善情况。结果观察组总有效率94.6%,明显优于对照组的78.6%(P〈0.01)。结论磁珠耳穴贴压治疗偏头痛疗效肯定,总有效率优于西药治疗。 相似文献
16.
目的观察甲氧氯普胺对偏头痛的临床疗效和安全性。方法采用随机单盲对照法,实验组102例,口服甲氧氯普胺10mg/次,3次/d;对照组97例,口服维生素B6,20mg/次,3次/d,均连服15d。疗效评定,分别于服药后第15d、第30d各1次。结果甲氧氯普胺组的治疗效果明显优于维生素B6组(P〈0.001),无明显不良反应。结论甲氧氯普胺对偏头痛有肯定疗效,且不良反应小,安全。 相似文献
17.
The authors report a 50-year-old man with progressive left hemispheric atrophy, cognitive decline, infrequent seizures, and spells suggestive of complicated migraine. They discuss the association between migraine and cerebral hemiatrophy and suggest that the spectrum of acquired cerebral hemiatrophy may be broader than what has been commonly recognized. 相似文献
18.
19.
Petra M.C. Callenbach Lise P.M. Pels Paul G.H. Mulder Wim H.J.P. Linssen Rob H.J.M. Gooskens Jan L. van der Zwan Oebele F. Brouwer For the SUM Trial Group 《European journal of paediatric neurology》2007,11(6):325-330
About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands. 相似文献
20.
Objective: This international postmarketing observational study of flunarizine was designed to evaluate, in routine clinical practice,
the risk/benefit ratio of flunarizine in its approved indications, namely prophylaxis of migraine and treatment of vertigo.
Comparator drugs were propranolol in migraine and betahistine in vertigo. The study was carried out by 498 general practitioners
in Belgium, The Netherlands and Germany, whose participation had been requested by mail. In total 3186 patients were entered:
1601 in the two migraine cohorts and 1585 in the two vertigo cohorts.
Results:
In the migraine study, treatment results with propranolol tended to be somewhat better than those with flunarizine, but a
selection bias cannot be excluded. There was no clear difference regarding efficacy between flunarizine and betahistine in
the vertigo study. The safety evaluation focused on extrapyramidal symptoms (EPS) and depression. Overall, EPS were noted
in only four patients, two in the vertigo-betahistine and two in the migraine-flunarizine cohort. A total of 70 patients developed
depressive symptoms (34 in the flunarizine and 24 in the propranolol migraine cohorts, but only 7 in the flunarizine and 5
in the betahistine vertigo cohorts). Patients with migraine were clearly more prone to depression than patients with vertigo,
regardless of their treatment. Additional risk factors for depression were a history of depression, and, in the migraine flunarizine
cohort, a high number of previous migraine treatments.
Received: 23 October 1995/Accepted in revised form: 20 February 1996 相似文献